MLP Oncología

@MLPOncoData

Medicina Interna - Oncología #OncTwitter

Medellín, Colombia

Joined January 2012

41Following

704Followers

MLP Oncología@MLPOncoData · Jul 23

Consolidative radiotherapy in oligometastatic and oligoprogressive NSCLC: A systematic review sciencedirect.com/science/articl…

MLP Oncología@MLPOncoData · Jul 23

The Role of Stereotactic Body Radiotherapy in Oligometastatic Non-Small Cell Lung Cancer❗️🤔❓ mdpi.com/1718-7729/31/1…

MLP Oncología@MLPOncoData · Jul 22

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management acsjournals.onlinelibrary.wiley.com/doi/epdf/10.33…

MLP Oncología@MLPOncoData · Jul 22

First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data ascopubs.org/doi/10.1200/JC…

MLP Oncología@MLPOncoData · Jul 22

Ovarian Cancer: A Review jamanetwork.com/journals/jama/…

MLPOncoData's tweet card. This Review summarizes the diagnosis and management of high-grade serous ovarian cancer.

MLP Oncología@MLPOncoData · Jul 22

Osimertinib plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer astrazeneca.com/media-centre/p…

MLP Oncología@MLPOncoData · Jul 22

Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset esmoopen.com/article/S2059-…

MLPOncoData's tweet card. T4 is one of the most important prognostic factors in localized colon cancer (CC), especially in stage II (pT4N0). However, the optimal adjuvant treatment in this subset of patients remains unclear....

MLP Oncología@MLPOncoData · Jul 22

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer annalsofoncology.org/article/S0923-…

MLPOncoData's tweet card. Invasive lobular carcinoma (ILC) is the second most common type of breast cancer and is increasingly recognized as a separate entity from invasive breast cancer of no-special type. Here, we present...

MLP Oncología@MLPOncoData · Jul 20

Resectable stage III nSCLC -systematic review from EORTC lung cancer group-The most important factors determining resectability were nodal extensiveness and tumour invasiveness: single cN2 involvement and cT3N1 made disease resectable. lungcancerjournal.info/article/S0169-…

MLPOncoData's tweet card. Lung cancer remains amongst the most lethal cancers [1]. Around 30% of patients present with stage III disease, characterised as locally advanced or regional disease. Stage III NSCLC is highly...

MLP Oncología@MLPOncoData · Jul 17

The exposome of healthy and accelerated aging across 40 countries nature.com/articles/s4159…

MLPOncoData's tweet card. Nature Medicine - Analyses of the exposomes of populations across 40 countries found global disparities in healthy aging attributed to diverse biological, socioeconomic and political factors, with...

MLP Oncología@MLPOncoData · Jul 17

Motivo de consulta: “me mandaron a oncología porque no había cita con el urólogo”

149

MLP Oncología@MLPOncoData · Jul 17

Worse Survival and Gastrointestinal Toxicity Outcomes Among Patients Receiving Proton Pump Inhibitors During Checkpoint Inhibitor Therapy jnccn.org/view/journals/…

MLPOncoData's tweet card. Background: Immune checkpoint inhibitors (ICIs) for cancer carry a risk of immune-related adverse events (irAEs). Upper and lower gastrointestinal tract inflammation are common toxicities. Proton...

MLP Oncología@MLPOncoData · Jul 17

Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer nejm.org/doi/full/10.10…

MLP Oncología@MLPOncoData · Jul 10

Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced Non‐Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives onlinelibrary.wiley.com/doi/10.1111/17…

MLPOncoData's tweet card. Immune checkpoint inhibitor-based first-line therapy improves survival in advanced NSCLC, yet its efficacy is moderated by PD-L1 expression and genomic profiles. Real-world challenges, including...

202

MLP Oncología@MLPOncoData · Jul 10

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma ascopubs.org/doi/10.1200/JC…

MLP Oncología@MLPOncoData · Jul 9

Inappropriate Conclusions on Surrogate End Points in Early Breast Cancer Trials ‼️ ascopubs.org/doi/10.1200/JC…

118

MLP Oncología@MLPOncoData · Jul 9

Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial 🚫🔪 nature.com/articles/s4141…

MLPOncoData's tweet card. British Journal of Cancer - Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial

128

MLP Oncología@MLPOncoData · Jul 8

MLP Oncología@MLPOncoData · Jul 3

First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma: A Systematic Review and #MetaAnalysis jamanetwork.com/journals/jamao…

MLPOncoData's tweet card. This systematic review with meta-analysis synthesizes available data from recent studies evaluating the effectiveness of immunotherapy and targeted therapy combinations in patients with non–clear...

136

MLP Oncología@MLPOncoData · Jul 2

Efficacy and safety of omitting 5-fluorouracil bolus in combination chemotherapy regimens for gastrointestinal cancers: a systematic review and meta-analysis tandfonline.com/doi/full/10.10…

MLPOncoData's tweet card. This meta-analysis aimed to evaluate the impact of omitting the 5-FU bolus in chemotherapy regimens for gastrointestinal cancers on treatment efficacy and toxicity.We searched major databases and c...

109